The tradeoff is lower bioavailability compared to injectable semaglutide
As Novo Nordisk boosts Wegovy, Ozempic AD spend, analysis finds a rising tide lifts all boats for diabetes, weight-loss drugs
Additional considerations include: Dietary quality changes during weight loss programmes Increased urinary magnesium excretion in poorly controlled diabetes (though GLP-1 therapy typically improves glycaemic control) Concurrent medications that may affect magnesium status, such as proton pump inhibitors or diuretics It is important to note that routine magnesium monitoring is not currently recommended in NICE guidance (NG28) for patients on GLP-1 therapy
Potential Benefits People Are Hoping For (What the Evidence Says) Microdosing tirzepatide is considered an intriguing and potentially beneficial approach, as Dr
Pharmacies and online platforms dispense these injectables casually, often marketed as miracle weight-loss solutions
Stanford Medicine psychiatrist Anna Lembke, MD, author of Dopamine Nation: Finding Balance in the Age of Indulgence, recently outlined several key insights into how these drugs might influence addictive behaviors
